The team at TRI has industry experience that spans biotechnology and large multinational pharmaceutical companies. Expertise ranges from early discovery research, through clinical development, product life-cycle management, business development and licensing. The team works with TPC's world-class scientists and a select group of external advisors and opinion leaders to identify investment opportunities that are strategically sound and can be effectively managed and supported to ensure a win: win outcome for TRI and its partners.

Graeme Martin Ph.D.
Dr. Martin is President and CEO of TRI with day-to-day responsibility for operations. He brings more than 28 years of pharmaceutical R&D experience, primarily in multinational Pharmas (Wellcome; Glaxo Wellcome: Hoffman La Roche). He was responsible for the discovery and preclinical development of Zomig®, marketed worldwide for the acute treatment of migraine. More recently, Dr. Martin served as Chief Technical Officer at Telik Inc. with responsibility for technology and business development before establishing a Bay Area biopharmaceutical consulting operation, Discovery-Insight. Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.

Etsuya Matsutani, Ph.D.
Dr. Matsutani joined TRI as Senior Vice President in March 2007. He spent 20 years in pharmacology research at Takeda Pharmaceutical Company, including a sabbatical in Dr.Folkman's laboratory, Children's Hospital, Harvard Medical School. Subsequently, Dr. Matsutani headed up Takeda's oncology drug discovery activities, serving as Research Manager (Oncology) in the Pharmacology Research Laboratories. More recently, he has served as Senior Manager of Business Development at Takeda's headquarters for global licensing. Dr. Matsutani graduated and received his doctorate from Nagoya University, Japan, and spent several years as Research Fellow at National Institute of Genetics, Japan.

Juan M.E. Harrison
Mr. Harrison joined TRI as Vice President in January 2008. He brings more than 21 years of biopharmaceutical R&D, product licensing, business development and strategy experience. Most recently, Mr. Harrison was a partner with ProPharma Partners International, where he specialized in developing and implementing business and licensing strategy for emerging and established biopharmaceutical companies. Prior to this, he held senior business development positions at XenoPort Inc., PowderJect Inc., Connetics Corporation and Alza Corporation. In addition, Mr. Harrison held product development management and research positions at Alza, where he began his career in 1985. Mr. Harrison received his Bachelor of Sciences in Combined Sciences from Santa Clara University in California, USA.

Shingo Makino, Ph.D.
Dr. Makino is Manager, Scientific Evaluation at TRI. He has more than 14 years pharmaceutical research experience specializing in organic and computational chemistry, firstly with Ajinomoto and subsequently with Takeda Pharmaceutical Company. He is the principal inventor of two small molecule drug candidates, both of which reached Phase II clinical development. Recently Dr. Makino was responsible for establishing and managing external medicinal chemistry relationships for Takeda, especially in China. He received his Master’s degree in organic chemistry from Tokyo Institute of Technology, and obtained his Doctorate from Tokyo University, Japan.